Pfizer's Xalkori Approved In EU As First-Line NSCLC Treatment

The European Commission has approved a label update to expand the use of Pfizer Inc.'s Xalkori (criotinib) to first-line treatment of adults with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC).